Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics Regains Compliance with Nasdaq Listing Requirement

NEW YORK (GenomeWeb News) – Rosetta Genomics today said that it has regained compliance with a Nasdaq listing requirement regarding stockholders' equity.

The firm, which makes microRNA-based diagnostic products, said that it received notification from the Nasdaq Listing Qualifications Staff that it is now in compliance with a requirement that it have $2.5 million in stockholders' equity in order to remain listed on the Nasdaq Capital Market.

Last week, Rosetta said that it has regained compliance with another listing requirement — the $1 bid price for its stock. The firm recently effected a reverse one-for-15 reverse stock split, which was followed by a strong surge in its stock price.

It also announced last week that it had netted proceeds of about $6 million from a direct offering of 570,755 ordinary shares at $11.50 per share to certain investors.

In early Wednesday trade, shares of Rosetta were up 1 percent at $12.45.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.